NQMC Update Service: March 28, 2016 ► American College of Radiology

NQMC Update Service: March 28, 2016

Measure Summaries

American College of Radiology

• Diagnostic imaging: fraction of all screening mammograms that are interpreted as positive (abnormal) and have a tissue diagnosis of cancer within 12 months.

• Diagnostic imaging: fraction of all screening mammograms that are interpreted as positive (abnormal) and have a tissue diagnosis of invasive cancer within 12 months.

• Diagnostic imaging: mean CT report turnaround time (RTAT).

• Diagnostic imaging: mean MRI report turnaround time (RTAT).

• Diagnostic imaging: mean PET report turnaround time (RTAT).

• Diagnostic imaging: mean radiography report turnaround time (RTAT).

• Diagnostic imaging: mean ultrasound report turnaround time (RTAT).

• Diagnostic imaging: median dose length product (DLP) for CT abdomen-pelvis with contrast (single phase scan).

• Diagnostic imaging: median dose length product (DLP) for CT chest without contrast (single phase scan).

• Diagnostic imaging: median dose length product (DLP) for CT head-brain without contrast (single phase scans).

• Diagnostic imaging: median size-specific dose estimate (SSDE) for abdomen-pelvis CT with contrast (single phase scans).

• Diagnostic imaging: median size-specific dose estimate (SSDE) for chest CT without contrast (single phase scans).

• Diagnostic imaging: number of CT exams performed at the facility that were submitted to the Dose Index Registry.

• Diagnostic imaging: percentage of all computed tomography colonography (CTC) exams, either screening or diagnostic, with a clinically significant extracolonic finding, not otherwise known based on the history provided or based on a prior imaging procedure at the institution.

• Diagnostic imaging: percentage of cancers detected at screening mammography that are invasive carcinoma less than or equal to 10 mm or ductal carcinoma in situ (DCIS).

• Diagnostic imaging: percentage of CT exams with contrast performed that resulted in extravasation.

• Diagnostic imaging: percentage of exams with confirming colonoscopies for a greater than or equal to 10 mm polyp detected by CT colonography (CTC) (true positive rate).

• Diagnostic imaging: percentage of invasive cancers detected at screening mammography that are node negative.

• Diagnostic imaging: percentage of screening mammograms interpreted as positive (abnormal).

• Diagnostic imaging: percentage of screening mammograms where biopsy was recommended that have a tissue diagnosis of cancer within 12 months.

• Diagnostic imaging: percentage of screenings for lung cancer interpreted as positive (Lung-RADS Category 3 or 4).

• Diagnostic imaging: percentage of screenings for lung cancer with abnormal interpretation (Lung-RADS 3 or 4) that result in a tissue diagnosis of cancer within 12 months.

• Diagnostic imaging: percentage of screenings of lung cancer that were interpreted as positive (Lung-RADS category 3 or 4) and result in a tissue diagnosis of cancer within 12 months.

• Diagnostic imaging: percentage of surgical patients aged 18 years and older undergoing procedures with the indications for prophylactic parenteral antibiotics who have an order for prophylactic parenteral antibiotic to be given within 1 hour (2 if fluoroquinolone or vancomycin).